Physician profile
Kristi L Milowic
NPI 1992734263
$3,575.66
in general payments reported to CMS, 2019-2025
33 companies · $71.13 in 2025
The $71.13 reported for 2025 was less than what a typical Neurodevelopmental Disabilities (Pediatrics) provider received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $269 · 2021: $150 · 2022: $255 · 2023: $410 · 2024: $1,310 · 2025: $71.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $500.94 | 2020-2025 | Briviact, Nayzilam, Fintepla |
| Ironshore Pharmaceuticals INC. | $371.48 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $347.78 | 2021-2024 | Qelbree |
| Aquestive Therapeutics, INC. | $225.69 | 2019-2025 | |
| Corium, LLC | $182.11 | 2022-2024 | Azstarys |
| Eisai INC. | $178.73 | 2019-2023 | |
| Neurelis, INC. | $153.15 | 2023-2024 | Valtoco |
| Livanova USA, INC. | $149.40 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $128.18 | 2023-2024 | Epidiolex |
| Tris Pharma INC | $125.90 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $105.29 | 2019 | |
| Mallinckrodt Enterprises LLC | $94.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.68 | 2019-2022 | |
| Aucta Pharmaceuticals, INC. | $88.09 | 2024 | Motpoly Xr |
| Allergan, INC. | $86.14 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $82.64 | 2019-2022 | |
| Harmony Biosciences LLC | $73.88 | 2024 | |
| Biomarin Pharmaceutical INC. | $73.67 | 2019-2024 | Brineura |
| Aprecia Pharmaceuticals, LLC | $65.67 | 2020-2022 | |
| Abbvie INC. | $65.31 | 2023-2024 | |
| Rhodes Pharmaceuticals L.P. | $59.54 | 2019 | |
| Greenwich Biosciences, INC. | $58.76 | 2019-2020 | |
| Immedica Pharma US, INC. | $43.82 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $32.08 | 2024 | Lumryz |
| Ipsen Biopharmaceuticals, INC | $31.74 | 2023 | Dysport |
| Sk Life Science, INC. | $26.68 | 2023 | |
| Biogen, INC. | $25.06 | 2024 | Spinraza |
| Upsher-Smith Laboratories LLC | $22.18 | 2019 | |
| Amneal Pharmaceuticals LLC | $21.64 | 2023 | Lyvispah |
| Vertical Pharmaceuticals, LLC | $18.80 | 2019 | |
| Collegium Pharmaceutical, INC. | $18.17 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $16.54 | 2023 | Methylphenidate Hydrochloride |
| Boston Scientific Corporation | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Milowic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.